Últimas noticias sobre Cardinal Health (NYSE:CAH) Bolsa

Cardinal Health

Cardinal Health is one of three leading pharmaceutical wholesalers in the us, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and McKesson, the three comprise well over 90% of the us pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CSCO

OUST

SERV

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: EAT, SERV, CSCO, OUST y CAH.

5 acciones en el foco este miércoles: EAT, SERV, CSCO, OUST y CAH

Cardinal Health Inc

CARRIER ALLIANCE HLDGS by Carrier Alliance Holdings, Inc.

Carrier Alliance Holdings Inc

CELESTIAL ASIA SECS NEW by Celestial Asia Secs Holdings Ltd.

Celestial Asia Securities Holdings Ltd

Caro Holdings Inc

EVOLUTION MINING LTD ORD by Evolution Mining Ltd.

Evolution Mining Ltd

UBS LUX MSC CANA ETF

Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-01. Here's what investors need to know before the announcement.
Analysts estimate that Cardinal Health will report an earnings per share (EPS) of $1.62. 
The announcement from Cardinal Health is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.11, leading to a 1.46% increase in the share price on the subsequent day.
Here's a look at Cardinal Health's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.73</td>
<td>1.95</td>
<td>1.60</td>
<td>1.41</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.84</td>
<td>2.08</td>
<td>1.82</td>
<td>1.73</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-4.0%</td>
<td>-2.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730383271_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Cardinal Health were trading at $107.89 as of October 30. Over the last 52-week period, shares are up 8.19%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/CAH/earnings">To track all earnings releases for Cardinal Health visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Cardinal Health

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $125 to $134.

Price Target

Analyst Ratings

UBS Maintains Buy on Cardinal Health, Raises Price Target to $134

Cardinal Health Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cah#NYSE">CAH</a>) is well-poised for growth, given its acquisition-driven strategy, a diversified product portfolio and a robust pharmaceutical segment. However, inflationary pressure remains a concern.
Shares of this Zacks Rank #3 (Hold) company have risen 11.1% in the year-to-date period against the industry&#39;s 1.7% decline. The S&amp;P 500 Index has gained 20.6% in the same time frame.&nbsp;
CAH, with a market capitalization of $27.09 billion, is a nationwide drug distributor and service provider to pharmacies, healthcare providers and manufacturers. The company has an earnings yield of 6.8% compared with the industry&#39;s 5.3%. It anticipates earnings to improve 9.6% over the next five years.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/ce/80495.jpg?v=1119199146" />
Image Source: Zacks Investment Research
<h2>What&#39;s Driving CAH&#39;s Performance?</h2>
Strength in Pharmaceutical Segment:&nbsp;Investors are upbeat about Cardinal Health&#39;s Medical and Pharmaceutical offerings, which provide the company with a competitive edge in the niche space.
The segment&#39;s products and services comprise pharmaceutical distribution, manufacturer and specialty services, and nuclear and pharmacy services, which are expected to majorly drive the quarters ahead. For the past few quarters, the segment has been acting as a key catalyst when it comes to driving growth.
In the fourth quarter of fiscal 2024, pharmaceutical revenues amounted to $55.6 billion, up 13% on a year-over-year basis. The performance reflects branded pharmaceutical sales growth from Pharmaceutical Distribution and Specialty Solutions customers.
The company expects revenues from its Pharmaceutical segment to decline 4-6% year over year in fiscal 2025. The anticipated decline reflects a $39 billion revenue headwind due to the OptumRx contract expiration in June 2024. Segmental profit is likely to increase 1-3% from the previous guidance of at least 1%.
Long-term Supply Agreements:&nbsp;Cardinal Health is also pursuing growth via joint ventures and long-term supply agreements with several firms, which have likely kept the investors interested. The company entered into a long-term strategic agreement with Henry Schein. Under this deal, Henry Schein purchased Cardinal Health&#39;s medical supplies for physician practices. The collaboration is expected to drive core sales and prove accretive to CAH&#39;s earnings in the long term.
The signing of a 15-year agreement with Bayer Healthcare for the contract manufacturing of Xofigo is significantly positive. In our opinion, this should help CAH leverage its expertise in the nuclear pharmacy industry to expand access to a therapeutic agent and increase the use of radiopharmaceuticals in the United States and Canada.
Strong Q4 Results:&nbsp;Cardinal Health&#39;s impressive fourth-quarter fiscal 2024 results buoy optimism. The company&#39;s robust top-line results and solid performance in the Pharmaceutical segment were encouraging. Per management, the segmental performance was driven by brand and specialty pharmaceutical sales growth from existing customers.
Gross profit increased 5% year over year, driven by segmental growth.
<h2>Notable Developments</h2>
Last month, CAH announced an agreement to acquire Integrated Oncology Network (&quot;ION&quot;) for $1.115 billion in cash. ION will enhance CAH&#39;s oncology strategy, adding value for providers and patients. The partnership aims to equip community practices with advanced tools and technology, along with expertise from Specialty Networks&#39; PPS Analytics and SoNaR technology, enabling the company to deliver high-quality, patient-centered care close to home, ultimately improving patient outcomes and strengthening CAH&#39;s leadership in healthcare.
Cardinal Health signed a distribution agreement with Australia-based Telix to become the commercial radiopharmaceutical distributor to supply finished unit doses of Telix&#39;s PET agent, Zircaix, for the imaging of kidney cancer in the United States, subject to regulatory approval.
In August, Cardinal Health announced the opening of a new distribution center in Greenville, SC. The distribution center is dedicated to the company&#39;s at-Home Solutions business, which is also expected to add roughly 200 jobs to the region over time. The opening of the new distribution center is likely to provide a boost to CAH&#39;s at-Home Solutions business and generate additional revenues to support the growing market for at-home solutions.
<h2>What&#39;s Weighing on the Stock?</h2>
Cardinal Health faces the risk of losing considerable business in case of loss of a major customer, which, in turn, can severely impair its future revenues. In this regard, post the establishment of a generic sourcing joint venture with CVS Caremark in 2014, Cardinal Health largely depends on the former for more than 20% of its revenues.
Collectively, five of Cardinal Health&#39;s main customers, including CVS, accounted for as much as 40% of its revenues. Meanwhile, the company&#39;s pharmaceutical distribution contracts with OptumRx ended in June 2024. These represented 17% of total revenues in fiscal 2023. The non-renewal of the contracts is likely to adversely impact CAH&#39;s sales in fiscal 2025.
In July, the FDA issued a warning for Cardinal Health&#39;s Presource kit plastic syringe makers, Jiangsu Shenli Medical Production Co. Ltd and Jiangsu China, who have been facing FDA investigation. Recent inspections have unveiled multiple quality system violations, leading to warning letters and import alerts. CAH has recalled the affected products to ensure patient safety and compliance with the FDA regulations.
<div class="chart_embed">
<h3>Cardinal Health, Inc. Price</h3>
<img alt="Cardinal Health, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/e8/1728295731.png" style="height:251px; width:583px" title="" />
Cardinal Health, Inc. price | Cardinal Health, Inc. Quote
</div>
<h2>Estimate Trend</h2>
The Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $215.84 billion, indicating a 4.9% decline from the previous year&#39;s level.
The Zacks Consensus Estimate for adjusted earnings per share is pinned at $7.61, indicating a 1.1% increase from the year-ago reported numbers. The consensus estimate for adjusted EPS has improved 1 cent over the past 30 days.
<h2>Stocks to Consider</h2>
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and&nbsp;Baxter International&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bax#NYSE">BAX</a>), each carrying a Zacks Rank #2 (Buy) at present.
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 14.58%.
Universal Health Service has gained 17.9% compared with the&nbsp;industry&#39;s&nbsp;19.8% growth in the past six months.
Quest Diagnostics has an estimated long-term growth rate of 6.2%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics&#39; shares have risen 14.3% in the past six months compared with the&nbsp;industry&#39;s&nbsp;8% growth.
Baxter&#39;s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 3.74%.
BAX&#39;s shares have lost 17.9% in the past six months against the&nbsp;industry&#39;s&nbsp;5.8% growth.
<a href="https://www.zacks.com/stock/news/2346905/reasons-to-retain-cardinal-health-stock-in-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2346905">To read this article on Zacks.com click here.</a>

Earnings Beats

Large Cap

Guidance

Health Care

Offerings

Contracts

Management

General

Reasons to Retain Cardinal Health Stock in Your Portfolio Now

Biotech

TTOO

T2 Biosystems Enters Multi-Year Exclusive U.S. Agreement With Cardinal Health To Sell FDA-Cleared Direct-From-Blood Diagnostics For Rapid Sepsis Detection, Including T2Dx Instrument, T2Bacteria Panel, And T2Candida Panel

Majorie Taylor Greene disclosed new stock transactions this week, which come as public efforts to ban members of Congress from trading continue to grow over <a href="https://www.benzinga.com/general/politics/24/05/39096827/exclusive-khanna-says-shameful-congress-members-profited-from-stocks-calls-for-trading-ban-makin">potential conflicts of interest.</a>
Here are the latest trades by the Republican House member from Georgia.
 What Happened: Greene has increased her frequency of trading disclosures <a href="https://www.benzinga.com/markets/equities/24/05/38611874/marjorie-taylor-greene-reveals-new-stock-trades-after-2-year-gap-berkshire-hathway-goldman-sachs">in recent months</a> with several large batches of stock purchases announced recently after a two-year hiatus of disclosures.
On Sept. 23, Greene disclosed her latest transactions, as reported by<a href="https://www.benzinga.com/gov-trades/members/marjorie-taylor-greene"> Benzinga's Government Trades page.</a>
Here are the stocks Greene bought, with each one disclosed as a value of $1,000 to $15,000:
<ul>
<li>Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</li>
<li>Berkshire Hathaway B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)</li>
<li>Blackstone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>)</li>
<li>Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</li>
<li>CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)</li>
<li>Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>)</li>
<li>Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>Southern Copper Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NASDAQ">SCCO</a>)</li>
<li>United Parcel Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>)</li>
</ul>
Several of these purchases add to recent stakes taken by the representative, including shares of Berkshire Hathaway, Microsoft and CrowdStrike.
The disclosure by Greene did not report any sale transactions, which means the congresswoman continues to hold her Trump Media &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares <a href="https://www.benzinga.com/general/social-media/24/08/40475137/djt-stock-hits-new-lows-since-trump-media-companys-public-debut-heres-how-much-marjorie-tayl">bought in October 2021.</a>
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent092524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Greene disclosed buying Digital World Acquisition shares back in October 2021, the SPAC that took Donald Trump's media company public in March 2024.
The transaction was done with shares trading between $67.96 to $118.80. A tweet from UnusualWhales pins the purchase price at $94.20, meaning Greene is down significantly on her $15,000 to $50,000 purchase in the Trump-linked stock. Shares of DJT trade at $13.63 at the time of writing.
Greene buying CrowdStrike shares continues to be an area to watch as <a href="https://www.benzinga.com/general/politics/24/07/39585140/marjorie-taylor-greene-buys-cybersecurity-stock-owned-by-nancy-pelosi-why-trade-could-draw-red-f">Benzinga previously reported</a> the representative sits on the Subcommittee on Cybersecurity, Information Technology and Government Innovation, which operates under the House Committee on Oversight and Accountability.
With the latest stock transactions, Greene has increased her holdings in technology stocks along with placing bets on Warren Buffett to continue powering Berkshire Hathaway along after the stock hit a $1 trillion market capitalization.
Not many can say that their investing portfolios are betting on Donald Trump and Warren Buffett, but Greene can.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent092524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo: Shutterstock

Government

Politics

CRWD

GOOG

INTC

LRCX

MSFT

SCCO

Marjorie Taylor Greene Stays Loyal To Trump, Keeps DJT Stock, Buys Into Warren Buffett's Berkshire In Latest Trades

Cardinal Health To Acquire Integrated Oncology Network For $1.115B, Expanding Navista Alliance With Over 100 Providers Across 50 Community-Based Sites In 10 States

Telix Selects Cardinal Health As A Commercial Radiopharmaceutical Distributor To Supply Finished Unit Doses Of Its PET Agent Zircaix For Imaging Of Kidney Cancer In US

Argus Research analyst David Toung maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $115 to $125.

Argus Research Maintains Buy on Cardinal Health, Raises Price Target to $125

The City of Baltimore, led by Mayor Brandon M. Scott, reached an $80 million settlement with Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) to resolve claims against the company for its role in the city&#8217;s opioid epidemic.
Under the agreement, Teva will pay an initial $35 million by the end of 2024, with the remaining amount due by July 1, 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40754258/jp-morgan-shows-most-interest-in-teva-organon-as-specialty-pharma-sector-exhibits-s" rel="noreferrer noopener">JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability</a>.
The <a target="_blank" href="https://mayor.baltimorecity.gov/news/press-releases/2024-09-09-city-baltimore-reaches-80-million-deal-teva-pharmaceuticals-resolve" rel="noreferrer noopener">settlement</a> is part of Baltimore's broader litigation strategy against opioid manufacturers and distributors.
Previous settlements with AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Allergan, CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), and Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) have brought in $322.5 million in total recoveries.
The ongoing legal battle will proceed to trial on Sept. 16 against the remaining defendants, who were responsible for more than half of the opioids distributed in Baltimore.
Mayor Scott emphasized the city's decision to opt out of the national Teva settlement, which would have yielded only $11 million over 13 years. Instead, the new agreement brings in more than seven times that amount in under a year.
Baltimore secured more than three times the funds it would have received from global settlements.
Baltimore will dedicate $5 million to education and outreach about the 988 crisis helpline, $3 million to the Penn North Recovery Center and $2 million to BMore Power.
Additional funds will be administered following the framework detailed in the executive order to address the ongoing epidemic.
In July, Teva announced topline results from its Phase 3 SPACE study evaluating the efficacy of Ajovy (fremanezumab) for the prevention of episodic migraine in children and adolescent <a href="https://www.benzinga.com/general/biotech/24/07/39843370/tevas-migraine-treatment-found-effective-for-children-as-young-as-6" target="_blank" rel="noreferrer noopener">patients aged 6-17</a>.
The trial met its primary endpoint with Ajovy achieving a statistically significant superior efficacy over 12 weeks of treatment compared to placebo.
TEVA Price Action: Teva stock is down 1.43% at $17.55 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40793504/viridian-therapeutics-discloses-exciting-data-from-experimental-thyroid-eye-disease-candidate-say" target="_blank" rel="noreferrer noopener">Viridian Therapeutics Discloses &#8216;Exciting&#8217; Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety</a>.</li>
</ul>
Photo: Ralf Liebhold via Shutterstock

Legal

ABBV

TEVA

Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies

The three largest U.S. drug distributors have reached a settlement of $300 million to resolve claims from health insurers and benefit plans over their alleged role in fueling the opioid epidemic, according to court documents filed on Friday.
The settlement involves McKesson Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), Cencora Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), and Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>). The proposed class action settlement, disclosed in a federal court in Cleveland, Ohio, requires a judge&#8217;s approval.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/06/39546645/unitedhealths-optumrx-settles-opioid-prescription-claims-for-20m" rel="noreferrer noopener">UnitedHealth&#8217;s OptumRx Settles Opioid Prescription Claims for $20M</a>.
Reuters highlights that the settlement comes on the heels of a $21 billion agreement by the same companies to settle claims from state and local governments.
Those claims accused the distributors of failing to implement proper controls, which allowed large quantities of addictive painkillers to be diverted into illegal markets.
The new settlement addresses the claims of third-party payers, such as union funds, who bore the financial burden of overprescribed and overmarketed opioid medications and the subsequent treatment of opioid use disorder.
The distributors did not admit any wrongdoing as part of the settlement. The $300 million payment will be divided among the companies, with McKesson paying 38.1%, Cardinal Health and Cencora paying 30.9% and 31%, respectively.
The case is part of a broader wave of litigation against drug manufacturers, distributors, and pharmacies, seeking accountability for a nationwide opioid crisis that has claimed hundreds of thousands of lives over the past two decades.
These lawsuits have collectively resulted in over $50 billion in settlements, primarily with state and local governments.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40691948/praxis-precision-medicines-touts-encouraging-data-for-mid-stage-epilepsy-drug" target="_blank" rel="noreferrer noopener">Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug</a>.</li>
</ul>
Image via Shutterstock

Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health Insurers

Cardinal Health Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cah#NYSE">CAH</a>) is a global pharmaceutical and medical products distributor serving over 100,000 hospitals. It&#39;s also the largest distributor of medical supplies and surgical products in the United States. Cardinal Health provides medical supplies and specialty therapeutics to 90% of the hospitals in the United States, as well as 60,000 pharmacies and over 10,000 specialty physician offices.
The rising trend in acute care utilization from emergency rooms, ambulatory and surgical care centers, and inpatient hospital visits has helped drive record results for the company. The stock is also a dividend aristocrat, having raised its dividend for nearly 40 consecutive years.
Cardinal Health operates in the medical sector with major healthcare services companies like McKesson Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mck#NYSE">MCK</a>), Stryker Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/syk#NYSE">SYK</a>), and Cencora Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cor#NYSE">COR</a>).
<h2>Cardinal Health&#39;s Massive Portfolio and Reach </h2>
The company&#39;s professional products range from durable medical equipment to anesthesia supplies, personal protective equipment (PPE), lab supplies, and surgical equipment. It carries over 46,000 home healthcare products to over 3.4 million patients. Its digital ecosystem supports medication adherence to over 23 million patients and over 60 payers. The company offers numerous tailored services, including data and analytics, to improve cost efficiencies, workflows, and waste reduction for ambulatory surgery centers, hospitals, pharmacies, and labs. They even provide customer packaging solutions to pharmaceuticals through its 60,000-square-foot facility with automated and semi-automated equipment accommodating small and large-volume batches and projects in compliance with all FDA standards.
<h2>Cardinal Health: Expanding Its Specialty Business </h2>
Cardinal continues to expand its specialty business, which focuses on distributing and servicing specialty pharmaceuticals, pharmacies, and physician practices. It offers technology platforms that help manage inventory, track patient outcomes, manage reimbursement cycles, and improve efficiency for pharmacies and practices. Specialty therapeutics include a wide array of high-cost, complex medications that often require special storage, handling, and patient support programs. In January 2024, the company agreed to acquire Specialty Networks for $1.2 billion in cash to accelerate growth in its Specialty business. &nbsp;
<img alt="Cardinal Health CAH stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20240818185626_chartb-cah.jpg" style="height:750px; width:915px" />
<h2>CAH Stocks Forms a Cup and Handle Breakout Pattern </h2>
The daily candlestick chart for CAH illustrates a cup and handle breakout pattern. The cup lip line at $105.08 was tested on Aug. 8, 2024. The pullback formed the handle staging the rally into its earnings release. CAH gapped to the cup lip line and proceeded to break out higher after testing the support for two days. The daily relative strength index (RSI) has bounced to the 75-band. Pullback support levels are at $105.08, $102.81, $98.79, and $96.05.
<h2>Cardinal Health Beats Top and Bottom Line Estimates </h2>
The fiscal fourth-quarter 2024 earnings report indicated strong top- and bottom-line acceleration. Cardinal Health reported EPS of $1.84, which beat the consensus analyst estimates for $1.74 by 10 cents. Its non-GAAP operating earnings rose 14% to $605 million. Segment profit increases in the Global Medical Products and Distribution and Pharmaceuticals and Specialty Solutions segments primarily drove the growth. Revenues grew 12.1% YoY to $59.87 billion, which also beat the consensus analyst estimate of $58.74 billion.
Fiscal 2024 operating cash flow and adjusted free cash flow reached all-time highs of $3.8 billion and $3.9 billion, respectively. Fiscal full-year 2024 revenues rose 11% YoY to $226.8 billion. Full-year non-GAAP diluted EPS rose 29% to $7.53.
<h2>Cardinal Health Raises Its Guidance </h2>
The company issued upside fiscal full-year 2025 non-GAAP EPS of $7.55 to $7.70 versus $7.53 consensus estimates, raising it from previous guidance of $7.50. Full-year revenue is expected to grow 10% to 12% YoY. Its Pharmaceutical and Specialty Solutions segment is expected to see revenues decline 4% to 6% YoY. Its Global Medical Products and Distribution (GMPD) segment is expected to see 3% to 5% revenue growth. Other revenue is expected to grow 10% to 12% YoY.
Cardinal Health CEO Jason Hollar commented, &quot;We delivered robust cash flow generation, continued profit growth in the Pharmaceutical and Specialty Solutions segment and significant improvement driven by our GMPD Improvement Plan. We enter the new fiscal year with momentum and confidence, evidenced by our raised fiscal year 2025 guidance.&quot;
CAH analyst ratings and price targets are at MarketBeat. There are 12 analyst ratings on CAH stock, comprised of seven Buys, two Holds, and one Sell. Consensus analyst price targets point to a 7% upside at $117.45.
The article &quot;<a href="https://www.nasdaq.com/articles/cardinal-health-soars-americas-leading-acute-care-supplier">Cardinal Health Soars as America&#39;s Leading Acute Care Supplier</a>&quot; first appeared on MarketBeat.

Dividends

Cardinal Health Soars as America's Leading Acute Care Supplier

JP Morgan analyst Lisa Gill maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Neutral and raises the price target from $111 to $123.

JP Morgan Maintains Neutral on Cardinal Health, Raises Price Target to $123

Cardinal Health Announced That Its Plans To Open A New Distribution Center In Walton Hills, Ohio, Supporting Its U.S. Medical Products And Distribution Business

Deutsche Bank analyst George Hill maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Hold and raises the price target from $115 to $119.

Deutsche Bank Maintains Hold on Cardinal Health, Raises Price Target to $119

Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) has outperformed the market over the past 5 years by 6.06% on an annualized basis producing an average annual return of 19.81%. Currently, Cardinal Health has a market capitalization of $26.35 billion. 
Buying $1000 In CAH: If an investor had bought $1000 of CAH stock 5 years ago, it would be worth $2,485.05 today based on a price of $108.05 for CAH at the time of writing.
<h3>Cardinal Health's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723820577_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Cardinal Health Stock In The Last 5 Years

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $120 to $125.

UBS Maintains Buy on Cardinal Health, Raises Price Target to $125

Wells Fargo analyst Stephen Baxter maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Underweight and raises the price target from $95 to $101.

Wells Fargo Maintains Underweight on Cardinal Health, Raises Price Target to $101

Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $114 to $119.

Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $119

Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) reported better-than-expected earnings for its <a href="https://www.benzinga.com/news/earnings/24/08/40364087/pharma-distribution-giant-cardinal-health-lifts-2025-guidance-after-q4-earnings-beat-raises-stock-b">fourth quarter on Wednesday.</a>
Cardinal Health reported fourth-quarter 2024 adjusted EPS of $1.84, up 29% year over year, beating the consensus of $1.73.
Sales increased 12% to $59.87 billion, beating the consensus of $58.64 billion. The pharmaceutical segment revenue increased 12% to $55.6 billion, driven by brand and specialty pharmaceutical sales growth from existing customers.
Cardinal Health raised its fiscal year 2025 adjusted EPS guidance to $7.55-$7.70 from the preliminary outlook of at least $7.50 versus the consensus of $7.53.
The company updated its Pharmaceutical and Specialty Solutions segment profit growth outlook to 1%-3% growth from at least 1%. For the Global Medical Products and Distribution segment, the company expects revenue growth of 3%-5%. Overall revenue is expected to grow between 10%-12%.
"We enter the new fiscal year with momentum and confidence, evidenced by our raised fiscal year 2025 guidance," said Jason Hollar, CEO of Cardinal Health.
Cardinal Health shares closed at $106.36 on Wednesday.
These analysts made changes to their price targets on Cardinal Health following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell</a> maintained Cardinal Health with an Outperform and raised the price target from $130 to $137.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5ece538c4a1e100001de8a1a/elizabeth-anderson">Evercore ISI Group analyst Elizabeth Anderson</a> maintained Cardinal Health with an In-Line and boosted the price target from $105 to $115.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40393013/pfizer-conagra-brands-and-2-other-stocks-insiders-are-selling">Pfizer, Conagra Brands And 2 Other Stocks Insiders Are Selling</a></li>
</ul>
Considering buying CAH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38-1024x574.png" alt="" class="wp-image-496733" style="width:414px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38.png 1216w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Cardinal Health Analysts Raise Their Forecasts Following Upbeat Earnings

Evercore ISI Group analyst Elizabeth Anderson maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a In-Line and raises the price target from $105 to $115.

Evercore ISI Group Maintains In-Line on Cardinal Health, Raises Price Target to $115

If I Had To Invest $150,000 Right Now, Here's What I Would Buy

My Top 3 Large Cap Magic Formula Stocks For October 2024

UBS' highest and lowest scoring 'quantamental signal' ideas

McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff

Dividend Champion, Contender, And Challenger Highlights: Week Of October 13

ONEV: Not Really A Low-Volatility ETF

McKesson, Cardinal Health draw ire of Sen. Warren over cancer deals

Notable companies reporting before tomorrow's open, with earnings consensus, include Exxon Mobil (XOM), consensus $1.88… Chevron (CVX), consensus $...

Notable companies reporting before tomorrow's open

Cardinal Health Q1 2025 Earnings Preview

Here's the major earnings before the open tomorrow

AAPL

ACDVF

ACGL

ACGLN

ACGLO

AMGN

AMZN

ANET

ARCB

ARES

AROW

ASIX

AVGO

AVNT

BANF

BFLY

BMYMP

CBOE

CBRE

CHCO

CHTR

CINF

CMCSA

CMLS

CSWI

CTRE

CTSH

CUBE

DBRG

DELL

EBAY

ESNT

EXPE

FDLO

FITB

FLIC

FMAO

FNLC

FOXA

FUBO

FUNC

GAIN

GILD

GOOGL

GSBC

GTLS

GWRS

HBNC

HSIC

IIPR

ILMN

INTT

INTU

INVH

IROQ

LECO

LGLV

LULU

MGRC

MNST

MPWR

MSGS

NVDA

NWFL

ODFL

ONEV

ORCL

ORLY

OXLC

PAYX

PRLB

QQQM

RBCAA

REXR

RGCO

RGLD

SCHD

SCHG

SCVL

SEDG

SOXX

SPLG

SPLV

SSNC

STAG

TFII

THFF

TMUS

TRGP

TROW

TSCO

TSLA

TYBT

TYCB

USMV

VRSN

WDFC

YORW

Press Releases

Cardinal Health Reports Fourth Quarter and Fiscal Year 2024 Results and Raises Fiscal Year 2025 Guidance

Cardinal Health Board of Directors Approves Quarterly Dividend

Cardinal Health expands medical product distribution footprint in Northeast Ohio

Cardinal Health celebrates Greenville, South Carolina, distribution center opening

Children's Hospital Association and Cardinal Health commemorate World Suicide Prevention Day with continued focus on youth mental health

Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®

Cardinal Health to acquire Integrated Oncology Network, a physician-led independent community oncology network

Cardinal Health to Announce First-Quarter Results for Fiscal Year 2025 on November 1

Comments

Cardinal Health

Noticias

Últimas noticias sobre Cardinal Health (NYSE:CAH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL